Mastocytosis: Rare, Underdiagnosed, Potentially Fatal

Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it, say experts.

Related Keywords

New York ,United States ,El Paso ,Texas ,San Antonio ,Denmark ,University Of Texas ,American ,Danish ,Attilio Orazi ,Ruben Mesa ,University Of Texas Health ,International Consensus Classification Of Myeloid Neoplasms ,Drug Administration ,Leukemia Myeloma Congress ,World Health Organization Classification Of Tumours ,American Society Of Hematology ,Stanford Calif Cancer Institute Jason Gotlib ,University Of Chicago ,Texas Tech University ,Cancer Institute ,Jason Gotlib ,Myeloma Congress ,World Health Organization Classification ,Blue Book ,International Consensus Classification ,Myeloid Neoplasms ,Acute Leukemias ,Texas Health ,Blueprint Medicines ,American Society ,End Results ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Systemic Mastocytosis ,Mastocytosis ,Leukemia ,Cancer ,Alignant Neoplasia ,Arcinoma ,Neoplasm ,Clinical Research ,Clinical Trials ,Linical Studies ,Tyrosine Kinase Inhibitor ,Rlotinib ,Efitinib ,Matinib ,U11248 ,Unitinib ,Biologic Therapy ,Hematology ,Lymphoma ,Malignant Lymphoma ,Multiple ,